Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Andrew Brunner, MD
Andrew Brunner, MD, is from the
Massachusetts General Hospital at Harvard Medical School.
Articles by Andrew Brunner, MD
Shaping the Future of MDS Management: Expert Forecasts
Thomas LeBlanc, MD, MA
Myelodysplastic Syndromes
|
February 18, 2025
Drs. Thomas LeBlanc, Jamie Koprivnikar, and Andrew Brunner give their predictions for the future of MDS management.
View More
MDS Experts Discuss Long-Term Findings From the COMMANDS Trial
Jamie Koprivnikar, MD
Myelodysplastic Syndromes
|
February 18, 2025
An expert panel delves into new data regarding the long-term efficacy of luspatercept in MDS.
View More
What is the Connection between Hemoglobin Levels and Quality of Life in MDS?
Jamie Koprivnikar, MD
Myelodysplastic Syndromes
|
February 18, 2025
An expert MDS panel discusses patient reported outcomes, transfusion dependence, and time toxicity.
View More
Optimizing MDS Management: Key Takeaways from the COMMANDS Trial
Thomas LeBlanc, MD, MA
Myelodysplastic Syndromes
|
January 10, 2025
Discussing the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
View More
Navigating ESA Failure in MDS
Thomas LeBlanc, MD, MA
Myelodysplastic Syndromes
|
January 31, 2025
How to address ESA failure or ineligibility in patients with MDS...
View More
Exploring ESA Treatment Outcomes in Lower-Risk MDS: Expert Perspectives
Thomas LeBlanc, MD, MA
Myelodysplastic Syndromes
|
January 27, 2025
Results from a real-world analysis of post-ESA treatment outcomes in patients with lower-risk myelodysplastic syndrome.
View More
Panel Predicts the Future of MDS
Hana Safah, MD
Video Insights
|
January 24, 2024
The panel shares their outlook for the future of MDS research and treatment.
View More
Biomarker Analysis on Inflammatory Effect for Luspatercept Versus Epoetin Alfa in Patients with MDS
Hana Safah, MD
Video Insights
|
December 19, 2023
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
View More
Patient-Reported Outcomes, Quality of Life for Luspatercept Versus Epoetin Alfa in MDS
Hana Safah, MD
Video Insights
|
December 19, 2023
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
View More
Real-World Outcomes of Non-Transfusion-Dependent Patients with MDS Treated with Luspatercept
Hana Safah, MD
Video Insights
|
December 19, 2023
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
View More
Impact of Molecular Characteristics, Responses to Luspatercept in Patients with MDS
Hana Safah, MD
Video Insights
|
February 8, 2024
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
View More
Implications of the Full Analysis of the COMMANDS Trial of Luspatercept for MDS
Hana Safah, MD
Video Insights
|
December 19, 2023
Dr. Safah outlines the findings from the full analysis of the COMMANDS trial.
View More
Evolving MDS Treatment Options and the MEDALIST Trial
Hana Safah, MD
Video Insights
|
December 19, 2023
The panel discusses the evolution of MDS therapy.
View More
What Is the Current State of MDS Treatment, Care?
Hana Safah, MD
Video Insights
|
January 12, 2024
Dr. Safah gave an overview of myelodysplastic syndromes.
View More